Other Events ·
Nektar reports 63% of alopecia patients maintained hair regrowth after stopping treatment, initiates Phase 3 study
NKTRNektar Therapeutics
On October 1, 2026, Nektar Therapeutics released new data from its Phase 2b REZOLVE-AA clinical trial for alopecia areata and announced the initiation of a third Phase 3 study in atopic dermatitis. The Phase 3 ZENITH AA study for alopecia areata is scheduled to begin in early 2027, enrolling 850 patients with severe-to-very-severe disease. Clinical results showed that 63% of patients maintained a SALT Score ≤20 six months after stopping treatment, and the proportion achieving near-complete hair regrowth (SALT ≤10) doubled from 7% to 19% during this off-treatment period. Nektar Therapeutics is a clinical-stage biotechnology company developing treatments for autoimmune and chronic inflammatory diseases.